Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
2024年5月25日 - 2:16AM
Edgar (US Regulatory)
SECURITIES
AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT
OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16
UNDER
THE SECURITIES EXCHANGE ACT OF 1934
May, 2024
Commission File Number 1-15182
DR.
REDDY’S LABORATORIES LIMITED
(Translation of registrant’s name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
+91-40-49002900
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F x Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K
in paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer
must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized
(the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the
information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b)
under the Securities Exchange Act of 1934.
Yes
¨ No x
If “Yes” is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
EXHIBITS
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized
|
DR. REDDY’S LABORATORIES LIMITED
(Registrant) |
|
|
|
Date: May 24, 2024 |
By: |
/s/ K Randhir Singh |
|
|
Name: |
K Randhir Singh |
|
|
Title: |
Company Secretary |
Exhibit 99.1
|
Dr.
Reddy’s Laboratories Ltd.
8-2-337,
Road No. 3, Banjara Hills,
Hyderabad
- 500 034, Telangana,
India.
CIN
: L85195TG1984PLC004507
Tel
: +91 40 4900 2900
Fax :
+91 40 4900 2999
Email
: mail@drreddys.com
www.drreddys.com |
May 24, 2024
National Stock Exchange of India Ltd. (Scrip Code: DRREDDY-EQ)
BSE Limited (Scrip Code: 500124)
New York Stock Exchange Inc. (Stock Code: RDY)
NSE IFSC Ltd (Stock Code: DRREDDY)
Dear Sir/Madam,
| Sub: | Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations
and Disclosure Requirements) Regulations, 2015 |
This is in furtherance to our intimation dated
January 30, 2024, wherein we have informed that the Board has approved the fund infusion by way of investment in equity shares of Aurigene
Oncology Limited (“AOL”) (formerly, Aurigene Discovery Technologies Limited), a wholly-owned subsidiary of the Company, upto
an amount of Rs. 6,500 million, and AOL will make similar investment in equity shares of Aurigene Pharmaceutical Services Limited (“APSL”),
a wholly-owned subsidiary of AOL and a step-down wholly-owned subsidiary of the Company.
In this connection, we further inform that the
Company has made an investment of Rs. 649,99,98,032/- and AOL has allotted 9,70,14,896 equity shares of Rs.10 each at a premium of Rs.
57/- to the Company on May 23, 2024.
The details required under Regulation 30 of the
SEBI Listing Regulations, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, with respect to the above
fund infusion is given in Annexure enclosed herewith.
This is for your information and records.
Thanking you.
Yours faithfully,
For Dr. Reddy’s Laboratories Limited
K Randhir Singh
Company Secretary, Compliance Officer and Head-CSR
Encl: as above
Annexure
Disclosure under Part A Para A(i) of Schedule
III read with Regulation 30 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015
Sl.
No |
Particulars |
Description |
1 |
Name of the target entity, details in brief
such as size, turnover etc. |
Aurigene Oncology Limited (“AOL”) (formerly, Aurigene Discovery Technologies Limited), a wholly-owned subsidiary of the Company. The fund infused by the Company into AOL will be further invested in Aurigene Pharmaceutical Services Limited (“APSL”), a wholly-owned subsidiary of AOL, to support the capex and working capital requirements of APSL. The turnover of AOL for FY2024 was Rs.372 crores. |
2 |
Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arms-length” |
The investment in AOL is a related party transaction, as AOL is a wholly owned subsidiary and accordingly a related party to the Company. The investment is done based on valuation report of an Independent Valuer and on arm’s length basis. Except as stated above, the promoter/ promoter group/ group companies have no interest in AOL. |
3 |
Industry to which the entity being acquired
belongs |
AOL is a drug discovery and clinical stage biotech company, committed to bringing novel and effective therapeutics for the treatment of cancer. |
4 |
Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity) |
The fund infused by the Company into AOL will be further invested in Aurigene Pharmaceutical Services Limited (“APSL”), a wholly-owned subsidiary of AOL and step down wholly owned subsidiary of the Company, to support the capex and working capital requirements of APSL. |
5 |
Brief details of any governmental or regulatory approvals required for the acquisition |
Not applicable. |
6 |
Indicative time period for completion of
the acquisition |
AOL has allotted 9,70,14,896 Equity shares of Rs.10 each at a premium of Rs. 57/- to the Company on May 23, 2024. |
7 |
Nature of consideration- whether cash consideration or share swap and details of the same |
Cash consideration |
8 |
Cost of acquisition or the price at which
the shares are acquired |
Cash consideration of Rs. 649,99,98,032/- towards subscription of equity shares of 9,70,14,896 equity shares of Rs.10 each at a premium of Rs. 57/- |
9 |
Percentage of shareholding / control acquired and / or number of shares acquired |
AOL is a wholly owned subsidiary of the Company. |
10 |
Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief) |
AOL is a drug discovery and clinical stage biotech committed to bringing novel and effective therapeutics for the treatment of cancer. The company was incorporated on 10th of August 2001. The turnover of the company for the previous 3 years is shown in below table: |
|
|
FY 2024 |
Rs.372 Cr |
|
|
|
FY 2023 |
Rs.265 Cr |
|
|
|
FY 2022 |
Rs.290 Cr |
|
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 5 2024 まで 6 2024
Dr Reddys Laboratories (NYSE:RDY)
過去 株価チャート
から 6 2023 まで 6 2024